药学研究2017，Vol.36Issue(4)：243-245,3.DOI:10.13506/j.cnki.jpr.2017.04.015
吉非替尼的临床应用研究
Clinical application of Gefitinib
杨同江 1王全亮 1解李丽 1单衍强1
作者信息
- 1. 齐鲁制药〈海南〉有限公司,海南 海口 570314
- 折叠
摘要
Abstract
Gefitinib is an EGFR inhibitor.It is only effective in cancers with mutated and overactive EGFR.The CFDA approved gefitinib in 2005 for non-small cell lung cancer(NSCLC).It was approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies.On July 13,2015,FDA approved as a first-line treatment for NSCLC.The advancement of gefitinib in current clinic researches were reviewed in this article.关键词
吉非替尼/抗肿瘤/临床研究Key words
Gefitinib/Anticancer/Clinical progress分类
医药卫生引用本文复制引用
杨同江,王全亮,解李丽,单衍强..吉非替尼的临床应用研究[J].药学研究,2017,36(4):243-245,3.
